RxDoctor Payments Data

Amanda Guy

Family · Canton, OHNPI 1700242401

Payments from drug & device makers

$2,166in general payments, 2019–2025

Across 73 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$463
  • Convatec Inc.$419
  • AbbVie$199
  • Sumitomo Pharma America, Inc.$153
  • Urogen Pharma, Inc.$150
  • Lucid Diagnostics Inc.$125
  • plus $657 from 13 others

What the payments were for

  • Food & beverage$1,74881%
  • Education$41819%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc7$463
Convatec Inc.12$419
AbbVie(2 entities)12$199
Sumitomo Pharma America, Inc.7$153
Urogen Pharma, Inc.5$150
Lucid Diagnostics Inc.1$125
Tolmar, Inc.6$113
Merck4$108
Immunitybio, Inc.4$107
Medtronic4$98
Laborie Medical Technologies Corp.2$48
Urovant Sciences Inc2$33
Hollister Incorporated1$25
Teleflex LLC1$23
Pharmaand GmbH1$23
Cycle Pharmaceuticals Inc1$22
Johnson & Johnson1$22
Telix Pharmaceuticals1$19
Coloplast1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,166 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$38,878
Medicare patients
351
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron116$81,319
GemtesaVibegron25$13,702
ElmironPentosan Polysulfate Sodium11$11,338
Tamsulosin Hcl653$10,827
Mirabegron ErMirabegron13$4,901
Finasteride244$4,156
Trospium Chloride ErTrospium Chloride12$3,448
Methenamine Hippurate31$2,199
Dutasteride35$2,138
Potassium Citrate ErPotassium Citrate15$1,900
Cephalexin125$1,184
Oxybutynin Chloride ErOxybutynin Chloride54$1,046
Trimethoprim28$918
Tolterodine Tartrate ErTolterodine Tartrate20$864
Desmopressin Acetate13$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$463$81,319116 claims
Sumitomo Pharma America, Inc.Gemtesa$153$13,70225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →